PapersPMID:12915429
Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 8 weeks
- Dose studied, every finding
- standard-dose guggulipid 1000 mg or high-dose guggulipid 2000 mg, 3 times daily, for 8 weeks
- Population, every finding
- Healthy ambulatory community-dwelling adults with hypercholesterolemia eating a typical Western diet, Philadelphia area; standard-dose and high-dose guggulipid arms together vs placebo
No finding here moved its endpoint.
What did not
How to read these marks →“There were no significant changes in levels of total cholesterol, HDL-C, triglycerides, or VLDL-C in response to treatment with guggulipid in the intention-to-treat analysis.”
- No detected effect on total cholesterol (TC)
very limited
- No detected effect on HDL cholesterol
very limited
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Ambulatory, community-dwelling, healthy adults with hypercholesterolemia in the Philadelphia, Pa, metropolitan area eating a typical Western diet
- Participants
- 103
- Comparator
- placebo
- Duration
- 56 days
- Endpoints measured
- 6